Immune-evasive beta cells in type 1 diabetes: innovations in genetic engineering, biomaterials, and computational modeling

Иммунно-уклоняющиеся бета-клетки при сахарном диабете 1-го типа: инновации в области генной инженерии, биоматериалов и компьютерного моделирования
İsmail Can Karaoğlu, Doğukan Duymaz, Mudassir Mohammad Rashid, Seda Kızılel
2025-08-19

CRISPR/Cas9 gene editingbiomaterial encapsulationimmune-evasive beta cellsmachine learningtype 1 diabetes
Type 1 diabetes (T1D) is characterized by the autoimmune destruction of pancreatic beta cells, resulting in lifelong insulin therapy that falls short of a true cure. Beta cell replacement therapies hold immense potential to restore natural insulin production, but they face significant hurdles such as immune rejection, limited donor availability, and long-term graft survival. In this review, we explore cutting-edge advances in genetic engineering, biomaterials, and machine learning approaches designed to overcome these barriers and enhance the clinical applicability of beta cell therapies. We highlight recent innovations in genetic editing techniques, particularly CRISPR/Cas9-based strategies, aimed at generating hypoimmune beta cells capable of evading immune detection. Additionally, we discuss novel biomaterial encapsulation systems, engineered at nano-, micro-, and macro-scales, which provide physical and biochemical protection, promote graft integration, and survival. We mention that recent advances in machine learning and computational modeling also play a crucial role in optimizing therapeutic outcomes, predicting clinical responses, and facilitating personalized treatment approaches. We also critically evaluate ongoing clinical trials, providing insights into the current translational landscape and highlighting both successes and remaining challenges. Finally, we propose future directions, emphasizing integrated approaches that combine genetic, biomaterial, and computational innovations to achieve durable, scalable, and immunologically tolerant beta cell replacement therapies for T1D.
1
Beta cell replacement could restore natural insulin production in T1D, but immune rejection, limited donors, and poor long-term graft survival remain major barriers.
2
CRISPR/Cas9-based genetic engineering is being used to generate hypoimmune beta cells designed to evade immune detection.
3
Clinical translation shows both progress and persistent challenges; integrated genetic, biomaterial, and computational approaches are proposed to achieve durable, scalable, immunologically tolerant therapies.
4
Machine learning and computational modeling can optimize therapeutic outcomes, predict clinical responses, and support personalized beta cell replacement strategies.
5
Nano-, micro-, and macro-scale biomaterial encapsulation systems provide physical and biochemical protection while promoting graft integration and survival.

beta cell replacement therapies for type 1 diabetes, including engineered hypoimmune pancreatic beta cells and their biomaterial-encapsulated grafts

strategies and innovations for immune evasion, graft protection and integration, long-term survival, and clinical optimization of beta cell replacement therapies

Publication Details
Publication Date
2025-08-19
Journal
Frontiers in Immunology
Publisher
Frontiers Media
ISSN
1664-3224
Cited by
18
Access Type
Author Information
Authors
İsmail Can Karaoğlu
Doğukan Duymaz
Mudassir Mohammad Rashid
Seda Kızılel
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%